SeekingAlphaAugust 24, 2026 at 3:42 PM NY11 days ago

Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple

Acadia (ACAD) eyes Phase 2 remlifanserin Alzheimerâs psychosis results by September/October. Learn about the risks and revenue cushion from Daybue/Nuplazid.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha

Read at Source

Companies in This Story

BIIBBiogen Inc220.83− 1.64%

Companies in This Story

Related Stories